Resolve double positivity with CCD-free recombinant components


  • Many bee and wasp (hymenoptera) allergic patients have positive tests for both venoms (double positivity) but clinical reaction only to one of the insects.
  • CCD-free recombinant components can help differentiate if double positive venom extract tests are due to true co-sensitization to bee and wasp allergens or CCD-dependent cross-reactivity between venoms.


Differentiate bee and wasp allergy


  • Test with complete natural venom extracts for highly efficient and sensitive detection of bee and wasp venom sensitization.
  • Test with rApi m 1, rVes v 1, rVes v 5/rPol d 5 to discriminate between bee and wasp venom sensitization in cases of double-positivity to the complete venom extracts.
  • Marker for honey bee: rApi m 1
  • Markers for wasps: Vespula: rVes v 1, rVes v 5, Polistes: rPol d 5
  • Marker for cross-reactivity between several venom allergen components: CCD


Improve patient management


  • Indications for SIT are based on documented true sensitization to the respective offending insect.
  • Selection of correct venom(s) for SIT treatment should be based on identification and inclusion of patients sensitized to true venom allergens. Recombinant venom components provide this information and exclude CCD cross-reactivity.
  • Detailed risk assessment and appropriate treatment of venom allergic patients improves their quality of life.
  • Baseline tryptase should be determined in all venom allergic patients before start of SIT, since patients with elevated tryptase levels are at a higher risk of severe reactions.